Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026
Company Drug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs

Fineline Cube Apr 21, 2023

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial

Fineline Cube Apr 21, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Company Deals Drug

Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results

Fineline Cube Apr 20, 2023

Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Paclitaxel-Coated Balloon Dilation Catheter

Fineline Cube Apr 20, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy

Fineline Cube Apr 20, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials

Fineline Cube Apr 20, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 20, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Drug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment

Fineline Cube Apr 20, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...

Company Drug

Walvax Biotechnology’s RQ3013 mRNA Vaccine Shows Efficacy in Phase III Study

Fineline Cube Apr 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the efficacy interim results of a...

Policy / Regulatory

NMPA’s 2022 Drug Supervision Report: Clinical Trials and Market Filings on the Rise

Fineline Cube Apr 20, 2023

The National Medical Products Administration (NMPA) has released its “Annual Drug Supervision and Administration Statistics...

Company Medical Device

Alcon Laboratories’ Innovative Intraocular Lens Approved by China’s NMPA

Fineline Cube Apr 20, 2023

The National Medical Products Administration (NMPA) has granted import approval to US firm Alcon Laboratories,...

Company Drug

Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma

Fineline Cube Apr 19, 2023

Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...

Company Deals

EOC Pharma Group Partners with China National Accord Medicines for Distribution Rights

Fineline Cube Apr 19, 2023

China-based EOC Pharma Group has announced a strategic partnership with compatriot firm China National Accord...

Company Deals

Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform

Fineline Cube Apr 19, 2023

Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...

Company Deals

Shanghai Huikai Medical Technology Secures Series A+ Funding for Prostate Stent System

Fineline Cube Apr 19, 2023

Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens...

Company Drug

Shandong Jincheng Pharmaceutical Initiates Phase II Study for LT-01 Antibacterial Drug

Fineline Cube Apr 19, 2023

Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233), China’s largest cephalosporin manufacturer, has announced receiving...

Company Deals

RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System

Fineline Cube Apr 19, 2023

RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...

Company Deals R&D

Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research

Fineline Cube Apr 19, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the...

Company Deals

Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China

Fineline Cube Apr 19, 2023

China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary...

Company Drug

Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...

Posts pagination

1 … 531 532 533 … 662

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.